Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug PHN-012 takes aim at Hard-to-Treat cancers

NCT ID NCT07127874

Recruiting now Disease control Sponsor: Pheon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, while also seeing if it can shrink tumors or slow disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma colon carcinoma colonic neoplasm colorectal adenocarcinoma lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER ADVANCED SOLID TUMORS COLON CANCER LUNG CANCER (NSCLC) PANCREATIC CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • PHN-012-001 Site

    RECRUITING

    Los Angeles, California, 90033, United States

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    San Diego, California, 92037, United States

  • PHN-012-001 Site

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • PHN-012-001 Site

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • PHN-012-001 Site

    RECRUITING

    St Louis, Missouri, 63108, United States

  • PHN-012-001 Site

    RECRUITING

    Durham, North Carolina, 27710, United States

  • PHN-012-001 Site

    RECRUITING

    Portland, Oregon, 97239, United States

  • PHN-012-001 Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • PHN-012-001 Site

    RECRUITING

    Houston, Texas, 77030, United States

  • PHN-012-001 Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • PHN-012-001 Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • PHN-012-001 Site

    RECRUITING

    Barcelona, Community of Catalonia, 08023, Spain

  • PHN-012-001 Site

    RECRUITING

    Barcelona, Community of Catalonia, 08035, Spain

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Madrid, Madrid, 28007, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28027, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28050, Spain

  • PHN-012-001 Site

    RECRUITING

    Valencia, Valencia, 46009, Spain

  • PHN-012-001 Site

    RECRUITING

    Valencia, Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.